IMNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunome Inc (IMNM) is not a strong buy for a beginner, long-term investor at this time. While analysts maintain positive ratings and see potential upside, the company's financial performance is weak, with significant revenue and net income declines. Technical indicators and trading signals do not suggest a compelling entry point, and the options data indicates bearish sentiment. Given the lack of recent news or significant catalysts, it is better to hold off on investing in this stock for now.
The MACD is below zero and negatively contracting, indicating bearish momentum. The RSI is neutral at 44.579, and moving averages are converging, showing no clear trend. Support and resistance levels suggest limited short-term price movement.
Analysts have maintained Buy and Overweight ratings, with price targets ranging from $30 to $40, citing a bolstered balance sheet, upcoming NDA filing, and potential catalysts in oncology assets.
No recent news or significant catalysts have emerged, and technical indicators do not suggest a strong upward trend.
In Q4 2025, revenue dropped to $0 (-100% YoY), net income declined to -$69.9M (-12.90% YoY), and EPS fell to -0.74 (-42.19% YoY). Gross margin remained flat at 100%.
Analysts maintain positive ratings with price targets ranging from $30 to $40. They highlight the company's strengthened balance sheet, potential catalysts in oncology, and reduced downside risk.
